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Abstract
Study Design: Mixed-method consensus process.
Objectives: Degenerative cervical myelopathy (DCM) is a common and disabling condition that arises when mechanical stress
damages the spinal cord as a result of degenerative changes in the surrounding spinal structures. RECODE-DCM (REsearch
Objectives and Common Data Elements for Degenerative Cervical Myelopathy) aims to improve efficient use of health care
resources within the field of DCM by using a multi-stakeholder partnership to define the DCM research priorities, to develop a
minimum dataset for DCM clinical studies, and confirm a definition of DCM.
Methods: This requires a multi-stakeholder partnership and multiple parallel consensus development processes. It will be
conducted via 4 phases, adhering to the guidance set out by the COMET (Core Outcomes in Effectiveness Trials) and JLA (James
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Lind Alliance) initiatives. Phase 1 will consist of preliminary work to inform online Delphi processes (Phase 2) and a consensus
meeting (Phase 3). Following the findings of the consensus meeting, a synthesis of relevant measurement instruments will be
compiled and assessed as per the COSMIN (Consensus-based Standards for the Selection of Health Measurement Instruments)
criteria, to allow recommendations to be made on how to measure agreed data points. Phase 4 will monitor and promote the use
of eventual recommendations.
Conclusions: RECODE-DCM sets out to establish for the first time an index term, minimum dataset, and research priorities
together. Our aim is to reduce waste of health care resources in the future by using patient priorities to inform the scope of future
DCM research activities. The consistent use of a standard dataset in DCM clinical studies, audit, and clinical surveillance will
facilitate pooled analysis of future data and, ultimately, a deeper understanding of DCM.
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Effectiveness Trials (COMET), James Lind Alliance (JLA), research priorities, Delphi, consensus, audit, surveillance, common data
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Introduction
Degenerative cervical myelopathy (DCM) is a common and
disabling disorder. It arises when degenerative changes in the
surrounding spinal structures exert mechanical stress on the
spinal cord and trigger a progressive injury.1 Such degenerative
changes include disc herniation, osteophyte formation, liga-
ment hypertrophy, or ossification.2 Patients may initially expe-
rience minimal symptoms,3,4 but subsequently often develop
pain, sensory deficits especially affecting their hands and feet,
spasticity, imbalance, bladder symptoms, and experience fre-
quent falls.1 Left untreated DCM can lead to spastic tetrapar-
esis.5 A recent study investigating quality of life in DCM
patients indicated they suffer among the worst SF36 health
scores of all chronic diseases.6
Due to widespread underdiagnosis, the true incidence and
prevalence of DCM is unknown. Current epidemiological stud-
ies quote the lifetime prevalence of DCM in the region of
0.5/1000.7 However, indirect experience suggests this is an
underestimation.1 For example, in a recent study of 181 healthy
volunteers aged between 40 and 80 years, radiological features of
DCM were seen in 59%, and diagnosis of DCM had been made
in only 1% of cases.3 Observational studies have demonstrated
that up to 22% of peoplewith asymptomatic spinal cord compres-
sion will go onto develop DCM.8,9 As a degenerative pathology,
the incidence is expected to rise with aging populations.
Surgery aimed at decompressing the spinal cord is the main-
stay of treatment.10 This is able to induce limited improve-
ments across a number of outcome domains.11 However,
owing to the limited intrinsic regenerative capacity of the
spinal cord,12 few patients make a complete recovery.13 As a
consequence, most patients suffer life-long disability.
Over the past 20 years, clinical research on DCM has signif-
icantly increased.14 This has clarified some basic tenets with
regard to the understanding and treatment of DCM, but many
questions remain unanswered, including fundamental aspects of
DCM pathology, the contribution of genetic predispositions, as
well as mechanisms by which DCM could be prevented and
recovery improved.15,16
Lack of Patient Involvement in the Design of Research
Risks It Not Addressing Patient Needs
In recent years, the importance of involving patients in the
design of research has become apparent. The term “research
wastage” was coined for research that does not result in health
care benefits for patients. In their seminal series, Chalmers et al
estimated that of the $240 billion invested in North American
health care research during 2010, 85% was misspent.17 They
identified a number of key contributory factors, including (1)
missing or ineffective research synthesis (eg, systematic
review), leading to research duplication, and (2) misalignment
of researcher and end-user objectives. These are equally appli-
cable with DCM.
Inconsistent Reporting of Research Findings
Compromises Research Synthesis
Efficient research synthesis requires 3 things: matched vari-
ables, reported in the same manner, and easily identifiable
studies. Recent systematic reviews indicated that clinical trials
in DCM do not use the same outcome measures or reporting
style.18 While some discrepancies can be overcome by acquir-
ing the original data, this is time-consuming, rarely straightfor-
ward, and often not possible.19 Moreover, the interpretation of
any pooled outcomes must also consider the comparability of
the studied population and the trial methodology. In DCM, this
is particularly pertinent due to the recognition that baseline
characteristics are important predictors of response to treat-
ment.20,21 This reporting is also inconsistent.22 Consequently,
studies are often excluded.11
DCM Lacks an Index Term That Enables Efficient
Literature Searches
DCM has recently been introduced as an umbrella term for a
number of degenerative conditions of the spine that result in
cervical myelopathy.23 While there has been good uptake
within the medical literature since its introduction, cervical
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myelopathy in its various etiologies lacks a recognized ICD
(International Classification of Disease) diagnostic code, Med-
ical Subject Heading (MeSH) for MEDLINE, or equivalent
grouping index term. Moreover, key search terms are not
unique: myelopathy can be caused by a range of other condi-
tions, degenerative pathology of the spine can occur in the
absence of DCM, and the surgical treatments can be applied
to other spinal conditions. This complicates literature searches
and research synthesis.24
Limited Involvement of Patients in DCM Research Design
May Lead to Misalignment of Research
A recent survey, conducted through Myelopathy.org, an inter-
national charity for those working with or directly affected by
DCM, explored the recovery priorities of individuals suffering
from DCM. The responses to the questionnaire indicated that
next to walking and hand function, which are often used as a
study outcomes,18,25 the number one priority was the resolution
of pain (Davies et al, unpublished data). In contrast to patient
responses, pain is however infrequently assessed in DCM trials
and reported by less than 25% of studies.18,22
In order to enable more efficient research synthesis and to
align research with patient needs, global initiatives have been
formed that aim to develop standards for researchers. These
processes use a multi-stakeholder consensus process to solicit
knowledge, experience, and judgement from stakeholders with
a broad range of direct interest on a particular issue and derive
shared and relevant agreement. Stakeholders are defined as
“individuals, organizations, or communities that have a direct
interest in the process and outcomes of a project, research or
policy endeavor.”26
Definition of Core Outcome Variables Aid Research
Quality and Synthesis
Organizations such as the Core Outcome Measures in Effec-
tiveness Trials (COMET) Initiative promotes the definition of
Core Outcome Set (COS) and additional data points (Core
Data Elements [CDE]) (Table 1). Often standards also define
how data points should be measured, referred to as a Core
Measurement Set (CMS).27-29 Apart from promoting compar-
ability among studies, such core outcome sets also reduce
reporting bias, a well-recognized issue in clinical research,
which leads to underrepresentation of negative research
findings.30
Definition of Priorities Help Align Research With Patient
Needs
The James Lind Alliance (JLA) is an organization supporting
the definition of research priorities31 by mediating “Priority
Setting Partnerships” (PSP), which aim to involve multiple
Table 1. RECODE-DCM Definitionsa.
Acronym Definition
DCM Degenerative cervical myelopathy —
MeSH Medical Subject Heading MEDLINE is a databaseof life science publications.MeSHare hierarchically organized
terminology for indexing and cataloguing its contents, to facilitate search.
JLA James Lind Alliance http://www.jla.nihr.ac.uk/—A nonprofit initiative to support and oversee the
establishment of healthcare research priorities.
PSP Priority Setting Partnership This process is carried out using a collaborative approach of relevant
stakeholders referred to as a PSP.
OMERACT Outcome Measures in Rheumatology www.omeract.org—An initiative supporting the development of consensus in
outcome measurement for arthritis.
COMET Core Outcome Measures in Effectiveness Trials http://www.comet-initiative.org/—A UK based organization supporting the
development of COS.
NINDS National Institute for Neurological Disorders
and Stroke
www.commondataelements.ninds.nih.gov—NINDS is the neurological arm of
the National Institute for Health, United States. They pioneered and continue
to support CDEs for neurological disorders.
COS Core Outcome Sets A set of agreed outcome variables and their measures to be reported in clinical
trials.
CDE Common Data Elements A set of agreed variables to be measured and reported in clinical trials
CMS Core Measurement Set A set of agreed tools used to measure outcomes or other data elements.
COSMIN COnsensus-based Standards for the selection
of health Measurement INstruments
http://www.cosmin.nl/—The COSMIN initiative aims to improve the selection of
health measurement instruments, by ensuring instruments have undergone
appropriate evaluation.
GRADE Grading of Recommendations Assessment,
Development and Evaluation
http://www.gradeworkinggroup.org/—A working group who developed a
transparent approach to grading quality (or certainty) of evidence and strength
of recommendations.
eDELPHI Electronic DELPHI An electronic system used to deliver the Delphi process over the internet.
a This consensus field is rich with acronyms, often bearing close resemblance in sentiment but different precise meaning. This table lists the acronyms used in this
protocol, including a summary (with link out resources where appropriate) of their meaning.
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stakeholders, including those affected by the condition, their
carers, and health professionals.
The significance of these standards is referenced by fund-
ing and regulatory bodies, such as the National Institute of
Health Research (NIHR) UK, the Food and Drug Administra-
tion (FDA) USA, and the European Medicines Agency
(EMA), who now seek assurances that proposed studies com-
ply with such policy.30
RECODE-DCM (REsearch Objectives and Common
Data Elements for Degenerative Cervical Myelopathy)
RECODE-DCM aims to reduce research wastage within the
field of DCM by using a multi-stakeholder partnership to
define the DCM research priorities, to develop a minimum
dataset for DCM clinical studies, and confirm a definition of
DCM suitable for establishment of a MeSH index term.
The natural evolution of DCM is unpredictable, and current
treatments do not alter the underlying degenerative processes.
Spinal cord compression may reoccur in individuals who have
undergone surgery1; consequently, recent international guide-
lines10 advocate lifelong surveillance for all patients with
DCM. However, the assessments suitable and necessary for
follow-up have not been defined. Similarly, benchmarks for
audit, to ensure effective practice, have not been established.
It is anticipated that the principal findings of RECODE-DCM
can be used to make such recommendations. As a secondary
objective, RECODE-DCM therefore aims to support clinical
practice, by defining clinically relevant subsets of CMEs for
clinical audit and clinical surveillance.
Methods
RECODE-DCM seeks to bring together stakeholders with lived
or professional experience from all phases of DCM clinical
care, including diagnosis and work-up, surgical treatment, non-
operative treatment, rehabilitation, and long-term follow up in
order to establish a COS, CDE, CMS, and PSP for use in DCM
clinical research and routine practice. The key objectives are as
follows.
1. To achieve consensus between key stakeholder groups
on the choice and definition of the umbrella term spe-
cific to this condition (index term)
2. To establish the top 10 research uncertainties (PSP)
3. To determine which outcomes are applicable and rele-
vant for use in clinical efficacy studies of patients with a
diagnosis (COS)
4. To determine which additional data elements are
required for the robust interpretation of outcomes
(CDE)
5. To determine how to measure agreed data points (CMS)
On this basis, the project also aims to make a pragmatic
recommendation of which data points and measurement tools
should be used in routine care to enable clinical audit and DCM
clinical surveillance. The challenge will be ensuring a valid and
comprehensive set, easily deliverable in routine care.
The overall delivery of the project will be overseen by a
steering group, who will meet at least twice a year in addition to
interim correspondence. Each meeting will include at least 2
people with lived experience and 4 professionals present to be
considered quorate. Where a steering group member is unable
to attend a meeting, decisions made at a quorate meeting will
be respected. The day-to-day administration of RECODE-
DCM will be overseen by a subcommittee, referred to as the
management group. These groups will ensure representation
from those with lived and professional experience of DCM,
and in addition the steering group will have representation from
the identified key professional subgroups. This process is reg-
istered with the COMET and JLA initiatives.32
The recommendations of supporting organizations, such as
NINDS, OMERACT, COMET, and JLA, alongside the
reported experience of completed processes have been incor-
porated into the following protocol.
RECODE-DCM can therefore be considered as a number of
different, but interlinked, work streams (Table 2). The index
term will be established using a Delphi process. The PSP will
use the Delphi process to inform a final and separate, face-to-
face consensus meeting. The COS will be established on the
basis of systematic reviews and qualitative interview work to
inform an online Delphi process and final face-to-face consensus
meeting. Similarly, the CDEwill be established using systematic
reviews to inform an online Delphi process and a final face-to-
face consensus meeting. The CMS will be established using
systematic reviews and the final COS, at a face-to-face consen-
sus meeting. Based on the findings of these phases, the steering
group will produce a pragmatic, distilled version or versions of
the COS/CDE for use in clinical audit and clinical surveillance.
We will streamline the process into 4 phases (Figure 1):
Phase 1 will consist of preliminary work, including a systema-
tic review and qualitative interviews for the COS and CDE. In
Phase 2, the Delphi process will take place. Phase 3 will incor-
porate the consensus meetings, and a final Phase 4 will monitor
Table 2. Route to Consensus.
Consensus Processes Consensus Stages/Tools
Index term  Delphi
Core Outcome Set (COS)  Systematic review þ
Qualitative interviews
 Delphi
 Consensus meeting
Common Data Elements (CDE)  Systematic review
 Delphi
 Consensus meeting
Priority Setting Partnership (PSP)  Delphi
 Consensus meeting
Core Measurement Set (CMS)  Systematic review (COSMIN)
 Consensus meeting
Clinical Subsets, for Audit
and Surveillance
 Consensus Meeting
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and promote the dissemination and use of the eventual
recommendations.
RECODE-DCM Work Streams
Each work stream will be discussed in turn. The components are
outlined in Table 2. Concepts specific to multiple processes,
such as the recruitment to and administration of the Delphi
process or consensus meetings, are outlined subsequently.
1. Definition of an Index Term
The index term will be established using the online Delphi.
A definition of DCM, developed by the steering group, will be
presented to stakeholders. Stakeholders will have the option to
approve or disagree with the definition. Those who disagree
will be required to provide their reasoning, including definition
amendments or alternative terms. If agreement is not reached,
further rounds will follow.
2. Definition of research priorities: The Priority Setting
Partnership (PSP)
The PSP sets out to establish the research uncertainties for
DCM. There is no limitation on the type of DCM patient or
phase of care. It will be established using an online Delphi
process and a final face-to-face consensus meeting. This will
be overseen by a JLA advisor.
Delphi. Round 1: Stakeholders will be asked to list their
research priorities and include a justification for their rea-
soning. To help prompt respondent reflection, priorities
will be sought in relation to the following themes: diag-
nosis, treatment, long-term care and other. There will be
no limit on the number of uncertainties that can be
submitted.
Data Processing: The results will then be processed. First,
research uncertainties will be grouped thematically, to identify
and remove duplicates. The unique uncertainties will then be
processed using the JLA Data Management Template, to iden-
tify if they are true uncertainties (ie, not already answered
through systematic review and termed “unrecognized
knowns”) and refine the information provided into an indica-
tive (summary) question. This information will then be
reviewed by the PSP steering group, where out of scope sug-
gestions will be removed from the process and indicative ques-
tions refined as applicable. Where possible, out of scope
uncertainties will be addressed separately, for example,
through dissemination to relevant organizations, or separate
research studies. It is intended a maximum of 60 uncertainties
Deﬁnion of Baseline Variables, Core Outcomes and
Research Priories
Phase 4: Adversement / Distribuon / Surveillance of Uptake
Phase 3: Consensus Meengs
Phase 2: DELPHI
Phase 1: Systemac Review and Qualitave Interviews
COSMIN
Assessment of
Outcome
Measures
Outcomes (COS) Baseline Variables (CDE) Research Priories (PSP) Index Term
Round 1 Round 1 Round 1 Round 1
Round 2 Round 2 Round 2
Meeng 3: Selecon of Instruments
Meeng 4: Subselecon for Audit and
Clinical Surveillance
Meeng 1: COS/CDE Meeng 2: PSP
Figure 1. Structure of RECODE-DCM.
RECODE DCM will be undertaken in 4 phases. Existing systematic reviews (Phase 1) will inform a Delphi consensus process (Phase 2), which in
turn will inform a final consensus meeting (Phase 3). It is anticipated the index term can be confirmed using the Delphi process alone. Phase 4 is
the dissemination of findings.
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will be presented in the second round of the Delphi. If more
than 60 have been generated, this will be refined by the steering
group, prioritizing those specific uncertainties, or uncertainties
within themes, raised in round 1, overall and by stakeholder
group.
Round 2: Following the collation and refinement, the
research uncertainties, now in the form of indicative questions,
will be re-presented to stakeholders, who will be asked to select
their top 10. Research uncertainties will be randomized to pre-
vent ordering bias.
Data Processing: The 20 to 30 research uncertainties most
frequently included in a top 10 will be taken forward to the
consensus meeting. Subgroup analysis, per stakeholder group,
and using GRADE ratings, will be undertaken to identify any
popular uncertainties not yet included, for example, those pre-
valent among individuals with lived experience, but not pro-
fessionals. The steering group will review this data and the
final list of uncertainties for inclusion in the final consensus
meeting.
PSP Consensus Meeting: “Priority Setting Workshop”. A face to
face consensus meeting will be held and facilitated by JLA
advisors, in order to select the final top 10 research priorities.
The complete audit trail from original data, to final indicative
uncertainties, will be kept and made publicly available on the
JLA website.
3. Definition of a Core Outcomes Set (COS)
The COS is primarily intended for use in clinical efficacy
studies of health interventions for use in DCM care. It will be
established using systematic reviews and qualitative interview
work to inform an online Delphi process and a final face-to-
face consensus meeting.
Systematic Review. A systematic review of outcome reporting in
DCM has already been conducted18; in short a broad search of
MEDLINE and EMBASE, using the search strategy “Cervical”
AND “Myelopathy” was undertaken for prospective clinical
trials of more than 50 patients, and retrospective clinical trials
of more than 200 patients, between the years of 1995 and 2015,
assessing DCM exclusively. The reported outcomes were col-
lated and presented with reference to their frequency and cho-
sen measurement instrument. The author group categorized the
reported outcomes by discussion and mutual agreement, into
the following domains: function, pain, complications, quality
of life, imaging and other.
Qualitative Interviews. Individuals with DCM and their care-
givers will be invited to attend a patient and public involve-
ment day, hosted at the University of Cambridge. Sufferers
and their caregivers will participate in separate small group
workshops, facilitated by an independent researcher experi-
enced in qualitative research, to ascertain the outcomes of
relevance to them. The groups will then be merged, and the
findings from these separate workshops shared. The concept
of outcome domains will then be outlined, and the combined
group tasked with developing a category system for their
defined outcomes. All interviews will be audio-recorded and
transcribed for analysis.
Delphi.Domains identified by the systematic review and from
the sufferer and supporter workshop will be reviewed by 2
researchers and someone with lived experience, to define the
key grouping themes. Outcomes identified from the systema-
tic review, and through content analysis of audio transcripts,
will then be mapped to a domain, having removed duplicate
or overlapping terms. Where there is uncertainty over
relevance or duplication, terms will be discussed among the
project management group, including a least one representa-
tive with lived experience and a health care professional.
Outcomes will then be put forward into a 2-round online
Delphi. These will be described using both lay and medical
terminology, after having been piloted among a small work-
ing group involving both those with lived and professional
experience.
Round 1: Participants within the COS Delphi will initially
be introduced to the process using plain English summaries,
available from COMET. Stakeholders will be presented with
the list of outcomes, grouped within each predefined outcome
domain and randomized to prevent ordering bias. GRADE rat-
ing will be completed. Stakeholders will be offered the oppor-
tunity to explain their reasoning and suggest other outcomes.
New outcomes will be reviewed by the project management
group, and if not already represented and within scope, will be
coded. Out of scope suggestions will be removed from the
process but retained separately and addressed as appropriate,
for example, via future studies, quality control projects, or
dissemination to relevant organizations.
Round 2: Stakeholders will then complete the survey again,
for variables without consensus or newly suggested outcomes,
including feedback from round 1. Specifically, they will be
able to review their scores: overall scores and score per cate-
gory of stakeholder for outcomes presented in the first round.
Any explanatory statements given in round 1 will be summar-
ized and reported. Outcomes will then be rated using the
GRADE system.
COS Delphi: Definition of Consensus. Outcomes meeting the Del-
phi consensus criteria (Table 3) will be included in the COS.
Outcomes meeting the definition for exclusion will be
removed, and the remaining outcomes will be taken forward
to the consensus meeting. Variables can be included directly
from the results of round 1, but only excluded after round 2 of
the Delphi process.
COS Consensus Meeting. Outcomes not yet included or excluded
will be reviewed at a face-to-face consensus meeting. Each
outcome will be reviewed in turn, with the feedback results
from round 2 of the Delphi presented to participants for refer-
ence. Following discussion, participants will vote for inclusion,
using the same GRADE profiling and consensus criteria (Table
3). If consensus for inclusion or exclusion is not established,
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further discussion will follow, and a second round of voting
will occur. For the second round, a threshold for inclusion of
60% score 7 to 9 and 20% score 1 to 3 will be set. If
consensus is not reached after 2 rounds, the outcome will not
be included in the COS.
The overall objective is to develop a COS with 10 or fewer
outcomes, with at least one outcome among the core areas of
adverse events, life impact, and pathophysiological manifesta-
tions. These core areas were chosen as relevant to DCM from
the care areas defined by OMERACT.33 If the a priori defini-
tion leads to the inclusion of too many outcomes, a nominal
group technique will also be used to refine the list of outcomes,
to establish an overall top 5, and a top 2 to 3 for professionals
and those with lived experience.
4. Definition of Common Data Elements (CDE)
The CDE is primarily intended for use in clinical efficacy
studies of health interventions for use in DCM care. It will be
established using systematic reviews to inform an online Del-
phi process and final face-to-face consensus meeting. The sys-
tematic review work has been completed.
Systematic Review. A systematic review of baseline reporting in
DCM clinical trials has been completed, using the aforemen-
tioned systematic search strategy.22 The baseline reporting of
outcome measures will be excluded, as these will be captured
by the COS; CONSORT statements require outcome measures
to be reported before and after intervention.34 The remainder
will be used to inform the Delphi process and referred to as data
elements. These will be arranged into convenient subgroups, as
defined by the project management group.
Delphi. Round 1: Participants within the CDE Delphi will ini-
tially be introduced to the process using plain English summa-
ries. Stakeholders will be presented with the list of data
elements, grouped as outlined above, randomized to prevent
ordering bias. Stakeholders will be asked to consider whether
or not a data element is essential for the evaluation of a DCM
patient in order to make a decision as to the appropriate treat-
ment. GRADE rating will be completed. Stakeholders will be
offered the opportunity to explain their reasoning and suggest
other data elements not listed.
New data elements will be reviewed by at least 2 members
of the research team, and coded if not already represented and
within scope.
Identified data elements will be cross-referenced with the
existing literature for their significance in outcome interpre-
tation, using references such as the recently updated systema-
tic reviews by Tetreault et al on prognostic factors in DCM
care21 or disease progression.35 Based on the literature, and
following discussion among the management group, each data
element will be assigned a certainty rating, as established by
GRADE.36
Round 2: Stakeholders will then complete the survey again,
for identified data elements, including feedback from round 1.
Specifically, they will be able to review their scores, overall
scores, and score per category of stakeholder for each data
element in the first round. They will also be presented with a
certainty rating, if such literature has been identified and a
rating assigned. Any explanatory statements given in round 1
will be summarized and reported. Elements will then be rated
using the GRADE system.
CDE Delphi: Definition of Consensus. Data elements with moder-
ate or high certainty of influencing outcome interpretation will
be included in the CDE. Data elements meeting the definition
for exclusion will be removed, and the remaining elements will
be taken forward to the consensus meeting. Consensus will be
assessed at the end of round 2 only.
CDE Consensus Meeting. Data elements not yet included or
excluded will be reviewed at a face-to-face consensus meeting.
Each element will be reviewed in turn, with the feedback
results from round 2 of the Delphi presented to participants for
reference. Following discussion, participants will vote for
inclusion, using the same GRADE profiling and consensus
criteria. If consensus for inclusion or exclusion is not estab-
lished, the data element will not be included in the CDE, that is,
only one round of voting will take place for data elements.
5. Definition of a Core Measurement Set (CMS) and Sub-
sets for Clinical Practice
Systematic Review. A synthesis of relevant measurement instru-
ments will be compiled. This will build on previous work18,37
and will include an assessment of their measurement
Table 3. A Priori Consensus Definitionsa.
Definition
“Consensus In,” one of: (1) 70% score 7-9 and 15% score 1-3 AND 50% score 7-9 per stakeholder group
(2) 90% score 7-9 within a single stakeholder group
“Consensus Out” 70% score 1-3 and 15% score 7-9 AND 50% score 1-3 per stakeholder group
“No Consensus” Neither of the above criteria are met
a “Consensus In” will be described as follows: (1)70% score 7 to 9 and15% score 1 to 3, with50% score 7 to 9 per stakeholder group; (2) Or90% score 7
to 9 for one stakeholder group (those with lived experience or health care professionals). “Consensus out” will be defined as15% score 7 to 9 and70% score
1 to 3, with 50% score 7 to 9 per stakeholder group.
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properties, as per the COSMIN criteria, for use in DCM. The
COSMIN search filter,38 including our own filter for DCM
research,24 will be used to facilitate this process.
CMS Consensus Meeting. This information will be presented to
the steering group in a subsequent and separate meeting,
although additional meetings may be required. The objective
of this meeting will be to select the most appropriate instru-
ment(s) for data points included in the CDE and COS. A sec-
ondary objective of this project is to develop a refined list of
data points from the CDE and COS suitable for clinical audit
and surveillance. Clearly this in itself could be a separate multi-
stage consensus process; however, pragmatically this is not
possible. Therefore, it will be left to the steering group to
establish this shortlist. Their decision will be informed by the
final CDE and COS, including the quantitative data from the
Delphi process and Consensus Meeting.
The Delphi Process
To improve efficiency, and reduce attrition among stake-
holders, participants will be recruited to a single Delphi pro-
cess. However, in order to reduce the burden on respondents,
and avoid confusion, participants will ideally be randomized to
1 of 3 parallel processes: CDE, COS, and PSP. All strata will
include assessment of the index term.
Stakeholders
Currently, there is no standard method for Delphi recruitment
nor a required stakeholder number. A fair representation of all
parties involved, worldwide, is thought to be key to deriving an
applicable and transferable consensus. This includes involve-
ment of participants from low- and middle-income countries.
The significance of patient involvement has already been out-
lined, and on that basis, we will aim for a 1:1 ratio of partici-
pants with lived experience to professionals.
Our recent diagnostic pathway analysis for the East of Eng-
land, United Kingdom, identified the key professional groups
involved in providing DCM care39: the majority (98%) of
patients underwent initial consultation with a general practi-
tioner, before referral to secondary care. Secondary care assess-
ment was mainly via neurology (45%) or a physiotherapy triage
service (45%), although other specialties including rheumatol-
ogy, geriatric medicine, and acute medicine were involved.
Most (98%) of patients received a treatment plan from a spinal
surgeon. Spinal surgeons play a key role in the field of DCM, as
the mainstay of treatment guidelines recommend all patients
have a spinal surgery opinion,10 moreover currently they dom-
inate the clinical research field.14 On this basis, within the
professional group we will aim for a 1:1 ratio between spinal
surgeons and other professionals (eg, other clinicians, allied
health professionals, and researchers).
Sampling
A dedicated study web page will be created, as both an infor-
mation resource related to the study and the single registration
point for participation. This information will outline the role of
a stakeholder, including the expected commitment and signifi-
cance of participation in all Delphi Rounds. Registration will
require respondents to provide selected demographics, includ-
ing age, gender, geographic location, and stakeholder group.
Respondents will also complete a conflict of interest disclo-
sure.40 The action of registration may favor continued partici-
pation,41 but will also allow live assessment of recruitment
strategies and adaptation of strategies if insufficient represen-
tation among subgroups is found.
Principally, patients will be identified through Myelo-
pathy.org, a DCM charity and online support community, sup-
ported with Google Adwords advertising. We have previously
utilized such strategies for the recruitment of DCM sufferers to
online surveys. This approach also enables Google Analytics to
be used to ascertain efficacy.42
For each professional subgroup national or international
representative bodies will be approached to advertise partici-
pation. As a project conducted in English, strategies will focus
on English-speaking countries, specifically America, Canada,
Australia, New Zealand, Ireland, and the United Kingdom.
However, some organizations have a broader reach, for exam-
ple, the AO Foundation or Cervical Spine Research Society,
and recruitment will extend beyond these counties. In addition,
key academic influencers will be identified through citation
analysis of DCM studies published over the last 5 years, with
approaches made to authors having published more than 3
DCM articles in this period. All registered participants will
be encouraged to promote the project among their colleagues
or patients.
Recruitment strategies will principally employ email or
social media. Piloted, promotional material will be used to
support these recruitment strategies. There are no recommen-
dations for set sample sizes to include in a Delphi study. Instead
a pragmatic approach will be taken, prioritizing balance across
stakeholder groups.
Administration
Recruited stakeholders will be divided into their matching
groups, namely, those with lived experience, spinal surgeons,
and other professionals. The sample size and representation will
be reviewed by the steering group. Ideally, stratified randomiza-
tion will then be undertaken, to ensure 3 equal groups meeting
the predefined criteria.43 Respondents will remain in the same
strata, with no crossover. However, if it is felt that there is
insufficient representation to allow 3 parallel Delphi processes,
the number of strata may be reduced.
Strategies identified from the literature to reduce attrition
between rounds, will be used, including pre-registration, use of
plain and clear language, regular updates, transparency regard-
ing time commitments, and personalized reminders.44,45
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Additionally, respondents completing all Delphi rounds will
receive a personalized certificate of participation and listing
as a collaborator to the RECODE-DCM study.46
Each list of items within the various Delphi surveys will be
accompanied by plain language descriptions, grouped into
categories and organized randomly at a category level and item
level. All items and descriptions will be reviewed by the steer-
ing group and may be piloted or externally reviewed to encour-
age development of survey language that all stakeholder groups
will equally comprehend.
Assessment of each item will largely be using the GRADE
process47; a 9-point Likert scale where a score of 1 is least
important and 9 most important. On occasion stakeholders will
be able to make suggestions or justify their answers as free text.
The a priori consensus definition is defined in Table 3.
The ambition is to complete the Delphi survey as outlined,
although if insufficient agreement has been made to facilitate a
consensus meeting this may be extended.
Sensitivity Analysis
The respondent rankings and choices will be analyzed by sub-
group to explore whether subgroups favored certain selections.
While the information will not be used within the eDelphi, at
the discretion of the steering group, these findings will be
presented at the consensus meeting, to support decision
making.
The Consensus Meetings
An international and multidisciplinary spine conference will
provide the platform for a face-to-face consensus meeting. In
addition to health care professionals and researchers involved
in DCM, patient and carer stakeholders will be invited. The aim
is to have a sample that is representative of the larger consensus
group, both in stakeholder makeup but also prioritizing indi-
viduals who have provided responses approximating the aver-
age opinion from the Delphi process. Invitations to the meeting
will be orchestrated to ensure fair representation of expertise
and demographic but will be weighted to the location of the
conference for convenience. Meetings will be facilitated by
those with trained experience, specifically for the PSP consen-
sus meeting which will be performed by JLA advisors.
Ethics and Dissemination
Ethical approval for the qualitative interviews, Delphi process,
and consensus meetings will be sought.
Myelopathy.org, an international charity and online plat-
form for those with the condition, carers, and professionals
interested in DCM, and AOSpine will host the eventual con-
sensus guidelines. They will act as a portal for supporting
information and assistance (if required). The COMET and
JLA databases will also be updated, and traditional journal
publication sought. A strategic dissemination plan will be
developed in concert with a health care public relations expert
(ES). Following a quality improvement strategy, methods of
advertisement and distribution will be evaluated periodically
and adapted over a 5-year period to track and accelerate
uptake of the guidance. Further professional bodies and fund-
ing partners will also be involved.
Discussion
The Delphi Approach Is a Proven Way of Reaching
Multi-Stakeholder Consensus
Consensus standards have been reached by a variety of meth-
ods, ranging from stand-alone meetings to more complex, mul-
tifaceted approaches.48 While there are some technical
differences, both the aforementioned organizations advise a
sequential Delphi process to inform a final face-to-face con-
sensus meeting. The Delphi method is well established with
regard to the development of consensus guidelines as it facil-
itates the refinement of multiple opinions into an accepted and
applicable recommendation.33,41 While a PSP has not previ-
ously been interwoven with a COS or CDE, their overlapping
methodology and the challenges of bringing multi-stakeholder
groups together offers an opportunity to meet both important
objectives, more efficiently. This will also provide an oppor-
tunity to define an index term.
Ensuring Adequate Representation and Participation
of Stakeholders
Adequate and balanced representation must be present at each
stage; within the steering group, the online surveys and the
final consensus meeting. Exactly what constitutes a balanced
makeup is yet not defined.49 This applies both to groups, but
also the number of representatives per group and the overall
weighting or proportions of each group. In the recent COS-
STAD guidelines key stakeholder groups were identified as
those who would use the CDE, health care professionals with
experience of the condition and patients and their representa-
tives.49 The guidelines were not able to define this further, but
it is recognized that the makeup will differ depending on the
objectives, for example, a PSP for breast reconstruction had a
large patient weighting that would seem logical as it is a largely
“body image”–based outcome.45
Online Surveys Are Efficient Tools to Reach Stakeholders
but Suffer From Attrition
The majority of information is collated and refined using online
surveys. The advantage of this is efficient access to large num-
ber of individuals from across the globe. We have recently
shown this in DCM.42 However, particularly if sequential sur-
veys are conducted, there is risk of attrition among participants,
which can lead to an overestimation of stakeholder agree-
ment.41 There is little published research on strategies to reduce
attrition within Delphi surveys but lessons from related pro-
cesses may be applicable: a Cochrane Review of patient
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recruitment to one-off electronic questionnaires identified a
number of factors which improved response rates, including
the benefit of short surveys.50 How transferable these findings
are to a serial process is unclear. Retention among randomized
controlled trial patients may be more pertinent, but findings of
a Cochrane Review again are not specific to an electronic
process.51 Alternative strategies specific to consensus pro-
cesses have sought to introduce efficiencies to reduce attrition.
For example in CDEs systematic reviews are often used to
inform the core domains, and the Delphi process is employed
to identify the measurement instruments.52,53 With regard to
PSPs, the JLA recommends the use of the steering group to
refine the number of research uncertainties before each stage.
Commonly, a degree of pragmatism is accepted to ensure
the project is deliverable,45 but the limitations of adaptations
must be noted. The steering group offers important oversight of
the process, and therefore must equally offer balanced repre-
sentation to prevent bias.
Conclusion
We propose an ambitious and comprehensive protocol,
designed to deliver recommendations that will shape the direc-
tion and improve the efficiency of future DCM research. For
the first time, RECODE-DCM will integrate consensus pro-
cesses to establish an index term, COS, CDE, and PSP. Our
aim is to improve the use of future resources to deliver efficient
research by using patient priorities to inform the scope of future
DCM research activities. The consistent use of a CDE in DCM
clinical studies, audit, and clinical surveillance will facilitate
pooled analysis of future data and, ultimately, a deeper under-
standing of DCM.
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